AOD9604 is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone (amino acids 177-191 of the full 191-amino-acid hGH molecule) with an additional N-terminal tyrosine residue. An intramolecular disulfide bond between the two cysteine residues in the sequence preserves a loop structure corresponding to the same loop in the parent hGH protein. The compound was developed by Metabolic Pharmaceuticals in the late 1990s as a candidate for clinical-research investigation of obesity-related indications. It is supplied as a research peptide for laboratory and analytical use only and is not an approved medicine for any indication.

What does 'AOD9604' stand for?

The 'AOD' portion of the name stands for 'Anti-Obesity Drug,' reflecting the original clinical-research program at Metabolic Pharmaceuticals that produced the molecule. The number 9604 is an internal program identifier from that development effort. The name reflects the developer's strategic positioning of the compound at the time of clinical investigation rather than a current clinical claim — AOD9604 did not become an approved anti-obesity medicine, and the clinical-research investigations did not produce a clear weight-loss signal of sufficient magnitude to support pharmaceutical approval. Despite this, the program name has been retained in the compound's identity.

Is AOD9604 growth hormone?

No. AOD9604 is not growth hormone. Growth hormone is a 191-amino-acid protein hormone produced by the pituitary gland. AOD9604 is a small synthetic 16-amino-acid peptide derived from the C-terminal region of growth hormone. Importantly, AOD9604 does not appear to activate the growth hormone receptor in the way the parent hormone does, and it does not produce the substantial IGF-1 elevation that full growth hormone signaling produces. The relationship is one of structural derivation — AOD9604 captures a specific region of the hGH sequence — but the two compounds belong to entirely different categories pharmacologically.

What is the C-terminal region of hGH?

The C-terminal region of human growth hormone refers to the end of the protein opposite the N-terminus — specifically, the last 15 amino acids of the 191-amino-acid full hGH sequence. In the folded hGH protein, the C-terminal region around amino acids 177-191 forms a loop structure on the surface of the molecule, stabilized by an intramolecular disulfide bond between cysteines at positions 182 and 189. Structure-function research dating to the 1970s and 1980s identified this region as associated with the lipolytic activity of growth hormone, which provided the conceptual rationale for the AOD9604 design program.

Does AOD9604 activate the growth hormone receptor?

In published research, AOD9604 does not appear to activate the growth hormone receptor in the way the parent hGH protein does, and it does not appear to engage the JAK2/STAT5 signaling pathway that mediates many of full hGH's biological effects. This is one of the scientifically distinctive features of AOD9604 — the lipolytic-relevant activity it exhibits in research models appears to operate through mechanisms other than growth hormone receptor activation. The detailed molecular mechanism is not fully resolved and continues to be investigated, but the absence of growth hormone receptor engagement is a consistent finding in the published literature.

Does AOD9604 raise IGF-1 levels?

In published research, AOD9604 has been reported not to produce substantial elevations of IGF-1 (insulin-like growth factor 1) in research models, consistent with its lack of growth hormone receptor activation. Full growth hormone signaling produces substantial IGF-1 elevation through stimulation of liver IGF-1 production, but AOD9604 does not appear to engage this axis in a comparable way. The dissociation between lipolytic-relevant activity and IGF-1 axis engagement has been a central feature of the AOD9604 research conversation and was part of the original development rationale for the compound.

Lipolysis is the biochemical process by which triglycerides stored in fat cells (adipocytes) are broken down into their components — free fatty acids and glycerol — which can then be released into the circulation and used by other tissues for energy or for further metabolism. Lipolysis in adipocytes is regulated by multiple signaling inputs, including beta-adrenergic signaling from catecholamines like norepinephrine and epinephrine, signaling from natriuretic peptides, signaling from growth hormone, and signaling from various other hormones. AOD9604 has been studied as a probe of how the C-terminal region of growth hormone influences this regulated lipolytic process in research models.

Did AOD9604 become an approved medicine?

No. AOD9604 did not become an approved medicine through the conventional pharmaceutical approval pathway. Metabolic Pharmaceuticals advanced the compound through clinical-research investigations in human obesity-related indications in the early-to-mid 2000s, but the studies did not produce a clear weight-loss signal of sufficient magnitude to support pharmaceutical approval, and the development program for that indication was discontinued. In a separate regulatory development, AOD9604 received recognition by the U.S. FDA as a Generally Recognized as Safe (GRAS) ingredient for use in certain food and dietary supplement contexts — a regulatory status distinct from approval as a pharmaceutical.

GRAS — Generally Recognized as Safe — is a U.S. FDA regulatory designation for ingredients used in food and dietary supplement products. The GRAS designation is a safety assessment for the specific uses described in the GRAS notice, made by qualified experts under the conditions of intended use. It is not an approval as a medicine or as a treatment for any condition. AOD9604 received GRAS recognition for use in certain food and supplement contexts in some jurisdictions, reflecting a safety assessment of the specific use cases described in the GRAS notice. The GRAS designation does not constitute clinical approval or efficacy approval for any indication.

Why did the clinical-research investigations not produce a weight-loss signal?

The clinical-research investigations of AOD9604 in human obesity-related indications in the early-to-mid 2000s did not produce a clear weight-loss signal of sufficient magnitude to support pharmaceutical approval. The reasons for this are not fully resolved and are themselves a topic of ongoing scientific discussion. Possible explanations discussed in the literature include the magnitude of lipolytic-relevant signaling produced by the compound at the doses studied, the complexity of human weight regulation involving multiple signaling systems beyond lipolysis alone, and the limitations of translating laboratory-research findings in adipocyte models into clinical effects on whole-body weight regulation in humans.

What is the disulfide bond in AOD9604?

The intramolecular disulfide bond in AOD9604 is a covalent bond between the two cysteine residues at positions 7 and 14 of the AOD9604 sequence (corresponding to positions 182 and 189 of the parent hGH numbering). This disulfide bond produces a small loop in the structure that mimics the corresponding loop in the natural hGH C-terminal region. The disulfide cyclization is an essential structural feature of AOD9604; without it, the linear unprotected peptide would have a different conformation and likely different biological activity. Reputable suppliers report on the disulfide-bonded form rather than the linear reduced form in their Certificate of Analysis.

How is AOD9604 supplied for research?

AOD9604 is typically supplied as a lyophilized — freeze-dried — powder in a sealed glass vial, packaged for research use. The lyophilized form is stable for extended periods when stored sealed at deep-freeze temperatures away from light. The intramolecular disulfide bond requires care in handling — exposure to reducing conditions can break the disulfide bond and convert the cyclic peptide to the linear form with potentially altered activity. Reconstituted material in aqueous solution is typically aliquoted into single-use portions for single-use thawing to avoid repeated freeze-thaw cycles and to limit exposure to conditions that could promote disulfide scrambling.

What is the relationship between AOD9604 and the natural hGH(177-191) fragment?

The natural hGH(177-191) fragment refers to amino acids 177 through 191 of the full human growth hormone sequence — a 15-amino-acid segment from the C-terminal region of the protein. AOD9604 is a modified version of this natural fragment: it includes the same 15 amino acids (positions 2 through 16 of AOD9604) plus an additional N-terminal tyrosine residue at position 1 that is not part of the natural hGH sequence. The N-terminal tyrosine was added in the design of AOD9604 in part to facilitate radio-labeling for analytical work. Both the natural fragment and AOD9604 share the intramolecular disulfide bond that preserves the loop structure of the C-terminal region.

Is AOD9604 a peptide hormone?

AOD9604 is a synthetic peptide derived from a region of a peptide hormone (growth hormone), but it does not itself fit the definition of a peptide hormone in the strict sense. A peptide hormone is typically defined as a peptide produced by an endocrine gland that is released into the circulation and acts on a specific receptor to produce defined biological effects. AOD9604 is a synthetic research peptide that does not appear to engage the growth hormone receptor and whose detailed molecular target or targets are not fully resolved. It is best described as a synthetic peptide derived from a hormone sequence rather than as a hormone itself.

How is AOD9604 different from GHRH analogs and GHRPs?

GHRH analogs (CJC-1295, Sermorelin, Tesamorelin) and GHRPs (Ipamorelin, GHRP-2, GHRP-6) act upstream of growth hormone release: they engage receptors on pituitary somatotrophs and stimulate the endogenous release of full growth hormone from the pituitary. AOD9604, in contrast, is a fragment of growth hormone itself and does not stimulate the release of endogenous growth hormone. The two categories of compound — upstream secretagogues and downstream fragments — are conceptually unrelated approaches to studying growth hormone biology. AOD9604 belongs to its own category as a designed C-terminal fragment with a distinct proposed mechanism that does not involve growth hormone release stimulation.

What is a Certificate of Analysis for AOD9604?

A Certificate of Analysis (COA) for AOD9604 is a document provided by a research-peptide supplier that reports the analytical characterization of a specific lot of material. The COA typically reports the sequence, the measured molecular mass by mass spectrometry, the purity by reversed-phase HPLC, and additional analytical metrics. For AOD9604 specifically, the COA should confirm that the material is in the disulfide-bonded cyclic form rather than the linear reduced form, because the disulfide cyclization is an essential structural feature of the compound. Reputable suppliers provide detailed COAs that allow researchers to verify these characteristics.

What is solid-phase peptide synthesis?

Solid-phase peptide synthesis, often abbreviated SPPS, is the standard laboratory method for assembling synthetic peptides one amino acid at a time on a small insoluble bead support. The growing peptide chain is anchored to the bead while each new amino acid is coupled in sequence using protecting-group chemistry. Most research-grade peptides — including AOD9604 — are produced through SPPS using Fmoc protecting-group chemistry. For cyclic peptides like AOD9604 with intramolecular disulfide bonds, the linear peptide is first assembled by SPPS, then the disulfide bond is formed in a separate oxidative folding step before purification by reversed-phase HPLC.

Is AOD9604 stable in solution?

Reconstituted AOD9604 has stability that depends in part on the conditions of the solution. The peptide backbone is reasonably stable at refrigerated temperatures over short periods. The intramolecular disulfide bond, however, is sensitive to reducing conditions and to disulfide scrambling that can occur under various conditions; exposure to free thiol groups or to reducing agents can break the disulfide and convert the cyclic peptide to the linear form with potentially altered activity. For this reason, reconstituted material is typically aliquoted into single-use portions, used promptly, kept refrigerated, and not exposed to reducing conditions; freeze-thaw cycles are avoided where possible.

Has AOD9604 been studied in cartilage or joint research?

Some published research has explored AOD9604 in the context of cartilage and joint biology in research models, including studies of effects on chondrocytes — the specialized cells of cartilage tissue. This research direction is exploratory rather than well-established and has produced findings that continue to be investigated in basic-science contexts. The cartilage-related research literature on AOD9604 is smaller than the adipocyte lipolytic-signaling literature, and findings should be read with the same care applied to any preclinical literature on a compound that has not been advanced through clinical-research investigation in that specific indication.

Where can I read the primary literature on AOD9604?

The primary literature on AOD9604 includes both basic-research publications and clinical-research reports from the Metabolic Pharmaceuticals development program in the early-to-mid 2000s. Heffernan et al. (2001) provides characterization of the compound's effects in adipocyte and animal-model systems. The published clinical-research reports from the obesity-related investigations are available through standard literature databases. The broader literature on hGH structure-function research from the 1970s and 1980s provides context for the design rationale of AOD9604. PubMed searches for 'AOD9604' and 'hGH 177-191' will return the relevant primary literature.

AOD9604 (with Bacteriostatic Water) lyophilized vial with bacteriostatic water for research

Swiss-SourcedPharmaceutical-GradeLyophilized PowderIn Stock≥99% Purity

In Stock

AOD9604 (with Bacteriostatic Water)

Name: AOD9604
Brand: Dr Jays Peptides
SKU: FC8842
Price: 41.00 USD
Availability: InStock

In Stock — ships from Jacksonville, FL

Free shipping over $300 — you're $300.00 away

SKU: FC8842

$41.00

Volume pricing

·5 mg

Sitewide sale price — extra discount by quantity on this line

Quantity	Price / Unit	Discount
5–9	$38.95	5%
10–15	$36.90	10%
16–20	$34.85	15%
21+	$32.80	20%

Dosage5 mg

100% Satisfaction Guarantee — damaged, incorrect, or off-spec orders are made right with a free reship or refund.
Flat-rate 2-day shipping (when available) from Jacksonville, FL · free shipping insurance on every order · free over $300.
Bacteriostatic water included — the correct amount for reconstitution, in every order.
Sourced direct from our Swiss pharmaceutical-grade manufacturer · Batch-traceable · Veteran-owned · 20% of profits donated to animal charities.
Secure checkout — powered by Shopify.

Accepted:

ZelleStripeBankful

Research use only — not for human or veterinary consumption.

What you receive

Sealed, lyophilized vial — 5 mg
Bacteriostatic water — appropriate size for reconstitution, included free
Certificate of Analysis available — view COAs

AOD9604 is a synthetic research peptide derived from a fragment of human growth hormone, studied in laboratory environments for its relevance to cellular signalling processes, peptide interaction pathways, and investigational models involving cellular metabolism and biological regulation. It is commonly explored in controlled research settings focused on peptide-based signalling mechanisms and biochemical pathway analysis.

Peptide FragmentMetabolic ResearchCellular SignallingLyophilized

Swiss-sourced · Pharmaceutical-grade · Cold-chain shipped

What researchers say

Real reviews from Dr Jays Peptides customers

Why Dr Jays vs. the alternatives

An honest side-by-side for researchers who care about what's in the vial

Purity guarantee

Dr Jays

98%+ guaranteed

Others

95–97% claimed

COA included with every order

Dr Jays

Others

Refund if purity fails

Dr Jays

Others

Same-Day shipping UPS

Cold storage — temperature controlled

Dr Jays

Others

Responsive human support

email reply in under 30 minutes

Dr Jays

Others

100% American made & sourced

Synthesized & fulfilled in the USA

Dr Jays

Others

Veteran owned & operated

Dr Jays

Others

Criteria	Dr Jays Peptides	Other peptide vendors
Purity guarantee	98%+ guaranteed	95–97% claimed
COA included with every order		~
Refund if purity fails
Same-Day shipping UPS Cold storage — temperature controlled
Responsive human support email reply in under 30 minutes		~
100% American made & sourced Synthesized & fulfilled in the USA
Veteran owned & operated